The largest real-world study published recently exploring the clinical value of cranial radiotherapy in osimertinib-treated EGFR-mutant NSCLC with BMs showed upfront cranial RT did not significantly improve iPFS, PFS, and OS in the whole population. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.